Corporate Overview
Thomas McLain
President & Chief Executive Officer
-
Mr. McLain brings to Vermillion more than 20 years of experience in executive management and corporate governance for both public and privately held companies, with a strong record of turning companies into leading players in the medical diagnostic and biotechnology industry.
Prior to joining Vermillion, McLain served as CEO and CFO of Claro Scientific, an early-stage diagnostic company where he brought commercial focus to the development of its broad platform technology. This included the implementation of a cost-effective research and clinical study program, executing upon a milestone-structured investor and strategic partnering program, and forming partnerships that funded and advanced the company.
Before Claro, he held various senior management positions at Nabi Biopharmaceuticals (now Biota Pharmaceuticals), a biotechnology company addressing immune system conditions. While serving as CEO, the company's market capitalization increased from $175 million to more than $1 billion within three years. Prior to Nabi, McLain held several senior management positions of increasing responsibility over 10 years at Bausch & Lomb, a global eye care company.
Donald G. Munroe, Ph.D.
Senior Vice President, Business Development & Chief Scientific Officer
Dr. Munroe has extensive experience in the diagnostic industry and has been a key member of senior management in a number of prominent diagnostic and life science companies. He served as Vice President, Immunoassay Research and Development from 2009 to 2011 at Beckman Coulter, a preeminent manufacturer of automated diagnostic tests and biomedical instruments. In this role, Dr. Munroe was responsible for launching key Immunoassay menu additions and re-standardizing existing assays.
William B. Creech
Vice President, Sales & Marketing
Mr. Creech was hired in March 2010 as the VP of Sales and Marketing. Most recently, Mr. Creech was VP Sales & Marketing at Capitol Vial, a subsidiary of Thermo Fisher Scientific, from March 2005 until September 2008. From March 1998 until March 2005, Bill was VP Corporate Accounts for Apogent Technologies and continued in that role when they were acquired by Fisher Scientific. He served as Director of Corporate Accounts at Chiron Diagnostics from 1995 to 1998.
Eric Schoen
Chief Accounting Officer
Mr. Schoen joined Vermillion in July 2010 as Corporate Controller. Prior to joining the Company, Mr. Schoen served as Revenue Controller for Borland Software from 2007 to 2010. From 2000 to 2007, he served in Corporate Controller and Director of Finance roles for Trilogy Enterprises, Momentum Software and Alticast, Inc. Mr. Schoen also spent nine years with PricewaterhouseCoopers, most recently as a Manager in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his Bachelor of Science in Finance from Santa Clara University.